1430 related articles for article (PubMed ID: 9171884)
21. Design of novel chimeric melanotropin-deltorphin analogues. Discovery of the first potent human melanocortin 1 receptor antagonist.
Han G; Quillan JM; Carlson K; Sadée W; Hruby VJ
J Med Chem; 2003 Feb; 46(5):810-9. PubMed ID: 12593660
[TBL] [Abstract][Full Text] [Related]
22. Cyclic analogs of alpha-melanocyte-stimulating hormone (alphaMSH) with high agonist potency and selectivity at human melanocortin receptor 1b.
Bednarek MA; MacNeil T; Tang R; Fong TM; Cabello MA; Maroto M; Teran A
Peptides; 2008 Jun; 29(6):1010-7. PubMed ID: 18378043
[TBL] [Abstract][Full Text] [Related]
23. Discovery and structure-activity relationships of novel alpha-melanocyte-stimulating hormone inhibitors.
Sawyer TK; Staples DJ; Castrucci AM; Hadley ME
Pept Res; 1989; 2(1):140-6. PubMed ID: 2562482
[TBL] [Abstract][Full Text] [Related]
24. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.
Getting SJ; Schiöth HB; Perretti M
J Pharmacol Exp Ther; 2003 Aug; 306(2):631-7. PubMed ID: 12750433
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors.
Grieco P; Lavecchia A; Cai M; Trivedi D; Weinberg D; MacNeil T; Van der Ploeg LH; Hruby VJ
J Med Chem; 2002 Nov; 45(24):5287-94. PubMed ID: 12431055
[TBL] [Abstract][Full Text] [Related]
26. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor.
Beyermann M; Fechner K; Furkert J; Krause E; Bienert M
J Med Chem; 1996 Aug; 39(17):3324-30. PubMed ID: 8765516
[TBL] [Abstract][Full Text] [Related]
27. Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors.
Haskell-Luevano C; Holder JR; Monck EK; Bauzo RM
J Med Chem; 2001 Jun; 44(13):2247-52. PubMed ID: 11405661
[TBL] [Abstract][Full Text] [Related]
28. Studies of conformational isomerism in alpha-melanocyte stimulating hormone by design of cyclic analogues.
Nikiforovich GV; Sharma SD; Hadley ME; Hruby VJ
Biopolymers; 1998 Sep; 46(3):155-67. PubMed ID: 9699465
[TBL] [Abstract][Full Text] [Related]
29. Aza-scanning of the potent melanocortin receptor agonist Ac-His-D-Phe-Arg-Trp-NH.
Boeglin D; Xiang Z; Sorenson NB; Wood MS; Haskell-Luevano C; Lubell WD
Chem Biol Drug Des; 2006 Apr; 67(4):275-83. PubMed ID: 16629825
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
[TBL] [Abstract][Full Text] [Related]
31. Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors.
Cai M; Marelli UK; Bao J; Beck JG; Opperer F; Rechenmacher F; McLeod KR; Zingsheim MR; Doedens L; Kessler H; Hruby VJ
J Med Chem; 2015 Aug; 58(16):6359-67. PubMed ID: 26218460
[TBL] [Abstract][Full Text] [Related]
32. beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity.
Haskell-Luevano C; Toth K; Boteju L; Job C; Castrucci AM; Hadley ME; Hruby VJ
J Med Chem; 1997 Aug; 40(17):2740-9. PubMed ID: 9276019
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of a novel potent cyclic peptide MC4-ligand by ring-closing metathesis.
Wels B; Kruijtzer JA; Garner K; Nijenhuis WA; Gispen WH; Adan RA; Liskamp RM
Bioorg Med Chem; 2005 Jul; 13(13):4221-7. PubMed ID: 15876540
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-D-Phe-Arg-Trp-NH2 at the mouse melanocortin receptors. 4. Modifications at the Trp position.
Holder JR; Xiang Z; Bauzo RM; Haskell-Luevano C
J Med Chem; 2002 Dec; 45(26):5736-44. PubMed ID: 12477357
[TBL] [Abstract][Full Text] [Related]
35. Design of novel melanotropin agonists and antagonists with high potency and selectivity for human melanocortin receptors.
Cai M; Mayorov AV; Ying J; Stankova M; Trivedi D; Cabello C; Hruby VJ
Peptides; 2005 Aug; 26(8):1481-5. PubMed ID: 15876475
[TBL] [Abstract][Full Text] [Related]
36. Substituted NDP-MSH peptides paired with mutant melanocortin-4 receptors demonstrate the role of transmembrane 6 in receptor activation.
Fleck BA; Ling N; Chen C
Biochemistry; 2007 Sep; 46(37):10473-83. PubMed ID: 17713970
[TBL] [Abstract][Full Text] [Related]
37. Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5.
Grieco P; Balse-Srinivasan P; Han G; Weinberg D; MacNeil T; Van der Ploeg LH; Hruby VJ
J Pept Res; 2003 Nov; 62(5):199-206. PubMed ID: 14531843
[TBL] [Abstract][Full Text] [Related]
38. Analogs of lactam derivatives of alpha-melanotropin with basic and acidic residues.
Bednarek MA; MacNeil T; Kalyani RN; Tang R; Van der Ploeg LH; Weinberg DH
Biochem Biophys Res Commun; 2000 May; 272(1):23-8. PubMed ID: 10872798
[TBL] [Abstract][Full Text] [Related]
39. Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities.
Mayorov AV; Cai M; Chandler KB; Petrov RR; Van Scoy AR; Yu Z; Tanaka DK; Trivedi D; Hruby VJ
J Med Chem; 2006 Mar; 49(6):1946-52. PubMed ID: 16539382
[TBL] [Abstract][Full Text] [Related]
40. Functional characterization of the modified melanocortin peptides responsible for ligand selectivity at the human melanocortin receptors.
Chen M; Georgeson KE; Harmon CM; Haskell-Luevano C; Yang Y
Peptides; 2006 Nov; 27(11):2836-45. PubMed ID: 16730390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
